THIRD INTERNATIONAL CONFERENCE ON THE VIRUS

正在申请资金以支持第三国际 水痘-带状疱疹病毒(VZV.上一首 1992年在马里兰州贝塞斯达举行了会议(与 与美国国立卫生研究院合作)和1994年在法国巴黎。这些活动的目的是 会议是为研究人员、院士和 参与VZV研究的临床医生将有一个科学论坛 交换。这次会议计划于1997年3月9日至11日举行。 1997年会议将重点讨论带状疱疹问题，特别是作为一个问题 ，但也将包括以下信息： 马鞭草。 VZV是引起水痘和带状疱疹的病原体。 (带状疱疹)，这两种都是人类的重要病原体， 带状疱疹是一种特别严重的医疗问题。 在50岁的人身上不仅可以表现为一种皮肤 皮疹，但也可能与持续支付的剧烈疼痛有关 在最初的疾病后几个月到几年，这种情况被称为 带状疱疹后神经痛(PHN)。会议将讨论的主题 1997年3月会议包括病毒复制、基因调控、 病毒-细胞蛋白相互作用，动物模型，潜伏期，宿主 答复，全部在会议的前半天，在 标题为“基础病毒学和病因学”。的主题 第二天和第三天包括诊断病毒学、流行病学、 使用抗病毒药物和疫苗，免疫功能低下的患者， 不同寻常的疾病临床表现，先天性综合征， 以及疼痛，因为它们与水痘和带状疱疹有关。具有特定的 关于带状疱疹，这将是会议的主要重点， 将讨论当前和未来的潜力 疫苗技术，治疗带状疱疹疼痛的新兴疗法，以及新的 关于VZV延迟的发现。

Funds are being requested to support the Third International Conference on the Varicella-Zoster Virus (VZV. Previous conferences were held in Bethesda, MD, in 1992 (in conjunction with NIH) and in Paris, France, in 1994. The purpose of these meetings is to provide a forum for researchers, academicians, and clinicians involved in VZV research to have a forum for scientific exchange. This meeting is planned to occur March 9-11, 1997. The 1997 meeting will focus on zoster, particularly as a problem for an aged population, but will also include information on vericella. VZV is the agent that causes vericella (chickenpox) and zoster (shingles), both of which are important pathogenes for humans, Zoster is particularly a medical problem for individuals over the age of 50 years in whom it can not only be manifested as a skin rash but also may be associated with severe pain that pay persist for months to years after the original illness, a condition termed post-herpetic neuralgia (PHN). Topics to be discussed at the meeting in March 1997 include virus replication, gene regulation, virus-cell protein interaction, animal models, latency, host responses, all on the first half-day of the meeting, under the heading of "Basic Virology and Pathogenesis." Topics for the second and third days include diagnostic virology, epidemiology, use of antivirals and vaccines, immunocompromised patients, unusual clinical manifestations of disease, congenital sysdromes, and pain, as they relate to varicella, and zoster. With specific regard to zoster, which is to be the major focus of the meeting, there will be discussions on the current and future potential of vaccine technology, emerging therapy for zoster pain, and new discoveries about VZV latency.